154 related articles for article (PubMed ID: 34612154)
1. Efficacy of ibrutinib as salvage treatment in a secondary central nervous system lymphoma (SCNSL) progressed after chemorefractory Primary Mediastinal B Cell Lymphoma (PMBCL).
Malfona F; Testi AM; Moleti ML; Petrucci L; Leccisotti L; Martelli M; Di Rocco A
Leuk Lymphoma; 2022 Feb; 63(2):483-486. PubMed ID: 34612154
[No Abstract] [Full Text] [Related]
2. Treatment with temozolomide and ibrutinib in recurrent/refractory primary (PCNSL) and secondary CNS lymphoma (SCNSL).
Renaud L; Bossard JB; Carpentier B; Terriou L; Cambier N; Chanteau G; Escure G; Tilmont R; Barbieux S; Wemeau M; Hieulle J; Boyle EM; Morschhauser F
Eur J Haematol; 2021 Sep; 107(3):370-373. PubMed ID: 34018260
[No Abstract] [Full Text] [Related]
3. Ibrutinib in primary central nervous system diffuse large B-cell lymphoma.
T Low J; B Peters K
CNS Oncol; 2020 Mar; 9(1):CNS51. PubMed ID: 32141313
[TBL] [Abstract][Full Text] [Related]
4. Ibrutinib for central nervous system lymphoma: the Australasian Lymphoma Alliance/MD Anderson Cancer Center experience.
Lewis KL; Chin CK; Manos K; Casey J; Hamad N; Crawford J; Ho SJ; Issa S; Grigg A; Wood P; Gandhi MK; Do B; Nastoupil L; Hawkes EA; Cheah CY
Br J Haematol; 2021 Mar; 192(6):1049-1053. PubMed ID: 32677095
[TBL] [Abstract][Full Text] [Related]
5. [Combination of ibrutinib and temozolomide for the treatment of newly diagnosed elderly primary central nervous system diffuse large B cell lymphoma: a case report].
Wang L; Li X; He YZ
Zhonghua Xue Ye Xue Za Zhi; 2020 Jun; 41(6):482. PubMed ID: 32654461
[No Abstract] [Full Text] [Related]
6. SOHO State of the Art Updates and Next Questions: Prophylaxis and Management of Secondary CNS Lymphoma.
Simard J; Roschewski M
Clin Lymphoma Myeloma Leuk; 2022 Oct; 22(10):709-717. PubMed ID: 35787364
[TBL] [Abstract][Full Text] [Related]
7. Primary central nervous system lymphoma: an unusual presentation.
Heckmann JM; O'Ryan S; Candy S
S Afr Med J; 2008 Nov; 98(11):851-2. PubMed ID: 19177889
[No Abstract] [Full Text] [Related]
8. Isolated central nervous system relapse of systemic lymphoma (SCNSL): clinical features and outcome of a retrospective analysis.
Patrij K; Reiser M; Wätzel L; Pels H; Kowoll A; Herrlinger U; Engert A; Linnebank M; Schackert G; Vogt-Schaden M; Egerer G; Lamprecht M; Batchelor TT; Schlegel U; Schmidt-Wolf IG;
Ger Med Sci; 2011; 9():Doc11. PubMed ID: 21698087
[TBL] [Abstract][Full Text] [Related]
9. Ruxolitinib shows activity against Hodgkin lymphoma but not primary mediastinal large B-cell lymphoma.
Kim SJ; Yoon DH; Kang HJ; Hong JY; Lee HS; Oh SY; Shin HJ; Kong JH; Yi JH; Sakamoto K; Ko YH; Huh J; Lee SS; Takeuchi K; Shin DY; Suh C; Kim WS
BMC Cancer; 2019 Nov; 19(1):1080. PubMed ID: 31707975
[TBL] [Abstract][Full Text] [Related]
10. Primary Mediastinal Large B-Cell Lymphoma As an Incidental Finding: Report of a Case.
Yönal-Hindilerden İ; Hindilerden F; Arslan S; Doğan İÖ; Nalçacı M
Turk J Haematol; 2018 May; 35(2):141-142. PubMed ID: 27094863
[No Abstract] [Full Text] [Related]
11. Liposomal-encapsulated doxorubicin supercharge-containing front-line treatment improves response rates in primary mediastinal large B-cell lymphoma and mediastinal gray zone lymphoma.
Picardi M; Giordano C; Pugliese N; Mascolo M; Varricchio S; Troncone G; Vigliar E; Bellavicine C; Lamagna M; Lisi D; Vincenzi A; Pane F
Hematol Oncol; 2024 Jan; 42(1):e3242. PubMed ID: 38126215
[No Abstract] [Full Text] [Related]
12. Liposomal-encapsulated doxorubicin supercharge-containing front-line treatment improves response rates in primary mediastinal large B-cell lymphoma and mediastinal gray zone lymphoma.
Picardi M; Giordano C; Pugliese N; Mascolo M; Varricchio S; Troncone G; Vigliar E; Bellavicine C; Lamagna M; Lisi D; Vincenzi A; Pane F
Hematol Oncol; 2024 Jan; 42(1):e3247. PubMed ID: 38287530
[No Abstract] [Full Text] [Related]
13. Axicabtagene Ciloleucel Chimeric Antigen Receptor T Cell Therapy in Lymphoma With Secondary Central Nervous System Involvement.
Novo M; Ruff MW; Skrabek PJ; Lin Y
Mayo Clin Proc; 2019 Nov; 94(11):2361-2364. PubMed ID: 31685159
[No Abstract] [Full Text] [Related]
14. Ibrutinib improves the efficacy of anti-CD19-CAR T-cell therapy in patients with refractory non-Hodgkin lymphoma.
Liu M; Deng H; Mu J; Li Q; Pu Y; Jiang Y; Deng Q; Qian Z
Cancer Sci; 2021 Jul; 112(7):2642-2651. PubMed ID: 33932067
[TBL] [Abstract][Full Text] [Related]
15. Rapid Resolution of Presumed Vitreoretinal Lymphoma With Systemic Ibrutinib Therapy.
Mathai M; Fein JG
Ophthalmic Surg Lasers Imaging Retina; 2021 Apr; 52(4):227-230. PubMed ID: 34039188
[TBL] [Abstract][Full Text] [Related]
16. Mediastinal large B-cell lymphoma with rosette formation mimicking thymoma and thymic carcinoid.
Tsai HW; Yen YS; Chang KC
Histopathology; 2006 Jul; 49(1):93-5. PubMed ID: 16842255
[No Abstract] [Full Text] [Related]
17. Molecular attributes underlying central nervous system and systemic relapse in diffuse large B-cell lymphoma.
Isaev K; Ennishi D; Hilton L; Skinnider B; Mungall KL; Mungall AJ; Bakhtiari M; Tremblay-LeMay R; Silva A; Ben-Neriah S; Boyle M; Villa D; Marra MA; Steidl C; Gascoyne RD; Morin R; Savage KJ; Scott DW; Kridel R
Haematologica; 2021 May; 106(5):1466-1471. PubMed ID: 32817292
[No Abstract] [Full Text] [Related]
18. Promising activity of selinexor in the treatment of a patient with refractory diffuse large B-cell lymphoma and central nervous system involvement.
Bobillo S; Abrisqueta P; Carpio C; Raheja P; Castellví J; Crespo M; Bosch F
Haematologica; 2018 Feb; 103(2):e92-e93. PubMed ID: 29242296
[No Abstract] [Full Text] [Related]
19. Clonal evolution in diffuse large B-cell lymphoma with central nervous system recurrence.
Magnes T; Wagner S; Thorner AR; Neureiter D; Klieser E; Rinnerthaler G; Weiss L; Huemer F; Zaborsky N; Steiner M; Weis S; Greil R; Egle A; Melchardt T
ESMO Open; 2021 Feb; 6(1):100012. PubMed ID: 33399078
[TBL] [Abstract][Full Text] [Related]
20. Pembrolizumab for refractory primary mediastinal B-cell lymphoma with central nervous system involvement.
de-la-Fuente C; Nuñez F; Cortés-Romera M; Franch-Sarto M; Ribera JM; Sancho JM
Hematol Oncol; 2021 Aug; 39(3):419-422. PubMed ID: 33369766
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
